The Pulmonary Function Testing and Evaluation Equipment industry has witnessed significant momentum over the past 18 months, driven by innovation and evolving healthcare demands. Strategic partnerships have emerged as a key trend, with companies collaborating to enhance diagnostic accessibility, such as agreements between device manufacturers and telehealth platforms to integrate remote pulmonary monitoring. In Mergers & Acquisitions, major players like RespirTech Global acquired PneumoSoft Solutions, bolstering their AI-driven diagnostics portfolio. Product/technology launches highlight advancements, including portable spirometry devices with AI-powered analytics, such as Viatel Health’s recent release of a cloud-connected PFT system. Regulatory changes in 2023, particularly FDA updates on digital health interoperability standards, have pushed firms to prioritize software integration and data security. A notable shift in consumer and enterprise trends underscores demand for point-of-care solutions, fueled by rising COPD and asthma prevalence. The sector also saw a surge in funding rounds, with startups like LungVision AI securing $28M in Series B financing to scale their AI-assisted PFT platforms. Looking ahead, sustainability initiatives and expansion into emerging markets are expected to shape the Pulmonary Function Testing and Evaluation Equipment industry trends in 2024.
